Lee’s Pharm of Hong Kong announced it will accelerate its development of a eye drop treatment for ophthalmic indications. In 2012, Lee’s in-licensed greater China rights to RGN-259 from RegeneRx Bio as part of a three-drug deal. Lee’s recently completed a new ophthalmic drug manufacturing and warehousing facility in Guangzhou. RGN-259 is a candidate for dry eye syndrome, neurotrophic keratitis (NK), and other persistent corneal disorders.
Source: China Biotoday
